title: [Research on inflammatory mediators in asthma: new therapeutic approaches].
abstract: During the National Meeting of Clinical Pharmacology (Giens 1998), the working group exchanged information and examined the new therapeutic approaches to inflammation in asthma. The group performed a state of the art review of the current research on mediators of bronchial inflammation to determine new pharmacological targets of therapeutic interest. An update on the development of potential drugs acting on these targets was established. Specificities related to asthma in terms of evaluation and development of anti-inflammatory drugs were discussed. The place of pharmaco-economy in the development of anti-asthmatic drugs was specified.
authors.affiliation: Service de Pneumologie, Hôpital Sainte Marguerite, Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Magnan
authors.forename: M
authors.initials: M
authors.lastname: Molimard
authors.forename: G
authors.initials: G
authors.lastname: Braunstein
authors.forename: P
authors.initials: P
authors.lastname: Devillier
mesh_terms: D018927:Anti-Asthmatic Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000191:economics / Q000276:immunology / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000502:physiology; D018925:Chemokines / Q000502:physiology*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000502:physiology; D003888:Desensitization, Immunologic; D016527:Drug Costs; D004804:Eosinophils / Q000276:immunology; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors / Q000502:physiology*; D053590:Interleukin 1 Receptor Antagonist Protein; D015289:Leukotrienes / Q000502:physiology*; D008213:Lymphocyte Activation; D008407:Mast Cells / Q000276:immunology; D018448:Models, Immunological; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019707:Receptors, Chemokine / Q000502:physiology; D018121:Receptors, Cytokine / Q000502:physiology; D012795:Sialoglycoproteins / Q000494:pharmacology; D018418:Th2 Cells / Q000276:immunology; D013928:Thromboxane A2 / Q000502:physiology
chemical_list: D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D015815:Cell Adhesion Molecules; D018925:Chemokines; D016207:Cytokines; C507763:IL1RN protein, human; D018836:Inflammation Mediators; D053590:Interleukin 1 Receptor Antagonist Protein; D015289:Leukotrienes; D010726:Phosphodiesterase Inhibitors; D011480:Protease Inhibitors; D019707:Receptors, Chemokine; D018121:Receptors, Cytokine; D012795:Sialoglycoproteins; D013928:Thromboxane A2